gracellbio.com (GRCL) - חוב להון עצמי

The financial price visualization for Gracell Biotechnologies (GRCL) demonstrates a total debt-to-equity ratio of 0.07. Gracell Biotechnologies (GRCL) relies on centers in the US and China, developing cutting-edge oncology treatments under the wing of a pharma behemoth. Its competitive advantage lies in the FasTCAR technology, which enables the preparation of drugs for critically ill patients within 24 hours. The acquisition by AstraZeneca provided the project with robust funding and a closed-loop development cycle.

This ratio compares total liabilities to equity, determining the degree of financial autonomy and the risk of default should borrowing costs change. By analyzing changes in the total debt-to-equity ratio, an investor can assess how aggressively Gracell Biotechnologies (GRCL) finances the development of accessible cell therapy methods, balancing the rapid scaling of innovation with the business's debt sustainability.